Literature DB >> 6823700

Primary adenocarcinoma of urinary bladder.

B N Nocks, N M Heney, J J Daly.   

Abstract

We reviewed the clinical course and pathologic findings of 17 patients with adenocarcinoma of the urinary bladder at Massachusetts General Hospital between 1962 and 1978. The 12 men and 5 women were between thirty-eight and eighty-six years old (mean, sixty years). Five patients had urachal adenocarcinoma, 8 had pure adenocarcinoma, and 4 had mixed adenocarcinoma and transitional cell carcinoma. Twelve of 17 patients (71 per cent) had muscle invasion (T2-T3), and none had evidence of regional or distant metastases at initial presentation. The mean follow-up was four years. The treatment modalities included transurethral resection alone in 3 patients, radical cystectomy in 4, simple cystectomy in 2, salvage radical cystectomy in 1, and partial cystectomy in 7, 3 of whom also received radiation therapy. Over-all crude three and five-year survival rates were 60 per cent and 27 per cent, respectively; patients with invasive disease did poorly regardless of treatment modality. Five of 8 patients who died had evidence of metastatic disease, and only 1 patient with invasive disease was alive more than five years. However, 2 of 3 patients with invasive urachal adenocarcinoma who had preoperative radiotherapy plus partial cystectomy are free of disease at thirty-eight and sixty months.

Entities:  

Mesh:

Year:  1983        PMID: 6823700     DOI: 10.1016/0090-4295(83)90117-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  2 in total

1.  A case report of primary upper urinary tract signet-ring cell carcinoma and literature review.

Authors:  Zhaohua Ye; Qiwu Mi; Daosheng Luo; Zhixiong Li; Jiexin Luo
Journal:  BMC Urol       Date:  2020-06-26       Impact factor: 2.264

2.  Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge.

Authors:  Somak Roy; Matthew A Smith; Kathy M Cieply; Marie B Acquafondata; Anil V Parwani
Journal:  Diagn Pathol       Date:  2012-11-02       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.